SUBSCRIBE
SUBSCRIBE
News   FDA

Swiss Approve Novartis International AG Drug For Blindness

August 29, 2006 | 
1 min read

ZURICH (Reuters) - Drugmaker Novartis AG said on Tuesday that Switzerland had become the first European country to approve the company’s Lucentis drug as a treatment for a leading cause of blindness in people over age 50.

FDA Approvals Europe
MORE ON THIS TOPIC
Amgen sign at its headquarters in Thousand Oaks, California, USA.
Approvals
Looking Beyond Obesity, Amgen Wins Colorectal Cancer Expansion for Lumakras
January 17, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: Exterior view of the headquarters of the
Complete response letters
Manufacturing Issues Result in FDA Rejection of Atara’s Cell Therapy
January 16, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
FDA signage at its headquarters in Maryland
Regulatory
After Letter to Commissioner, FDA Finally Gives Vanda Reason for Rejection, Chance for Hearing
January 16, 2025
 · 
2 min read
 · 
Tristan Manalac
Eli Lilly's biotechnology center in California
Immunology and inflammation
Lilly’s I&I Push Gains Momentum With Omvoh Expansion
January 16, 2025
 · 
2 min read
 · 
Tristan Manalac